THE WORLD BANK GROUP ARCHIVES

PUBLIC DISCLOSURE AUTHORIZED

Folder Title: Clausen Papers - Special Programme for Research and Training in Tropical

Diseases - Correspondence 02

Folder ID: 1774383

Dates: 10/1/1984 - 10/31/1984

Series: Alphabetical [subject] files

Subfonds: Records of President A. W. Clausen

Fonds: Records of the Office of the President

ISAD Reference Code: WB IBRD/IDA EXC-09-3957S

Digitized: 3/1/2019

To cite materials from this archival folder, please follow the following format:

[Descriptive name of item], [Folder Title], Folder ID [Folder ID], World Bank Group Archives, Washington, D.C., United States.

The records in this folder were created or received by The World Bank in the course of its business.

The records that were created by the staff of The World Bank are subject to the Bank's copyright.

Please refer to http://www.worldbank.org/terms-of-use-earchives for full copyright terms of use and disclaimers.



© International Bank for Reconstruction and Development / International Development Association or The World Bank 1818 H Street NW Washington DC 20433

Telephone: 202-473-1000 Internet: www.worldbank.org

CLAUSEN'S! Special Programme fort Training in Trapical Diseases
Research and



DECLASSIFIED WBG Archives



A1995-265 Other #: 18

Clausen Papers - Special Programme for Research and Training in Tropical Diseases - Correspondence 02

The two attached letters are examples of a group of 26 letters prepared by WHO for signature by Dr. Mahler of WHO, Brad Morse of UNDP and you. With Mr. Stern's agreement, we signed them in your name on the machine. The letters differ slightly in that one set is directed to those countries/institutions which are already participating in the Training in Tropical Diseases Program, and the other set is being sent to those which have never participated. I have listed the recipients below:

Those already participating

- Margaret Thatcher U.K.
- 2) Gustav Husak President - Czechoslovakia
- 3) Guillaume de Spoelberch General Manager - Aga Khan Foundation
- 4) Erich Honecker German Democratic Republic
- 5) Pal Losonczy Hungary
- 6) Datuk Seri Dr. Mahathir Mohamad Prime Minister - Malaysia
- 7) Prem Tinasulanonda Prime Minister - Thailand
- 8) David Russell Lange Prime Minister - New Zealand
- 9) Doo-Hwan Chun President - Korea
- 10) C.V. Devan Nair President - Singapore
- 11) Vojo Srzentic
 President Yugoslavia
- 12) Patrick Hillery
 President Ireland
- 13) Muhammadu Buhari Head of State - Nigeria
- 14) Dr. Richard von Weizsacker President - Fed. Rep. of Germany
- 15) Yasuhiro Nakasone Prime Minister - Japan
- 16) Ronald Reagan
 President U.S.
- 17) Franklin A. Thomas
 President Ford Foundation
- 18) Dr. Rudolf Kirchschlager
 President Austria

Those which have never participated

- Dr. R. C. Tress
 Director, The Leverhulme Trust
 U.K.
- 2) Margaret E. Mahoney President - The Commonwealth Fund N.Y.
- 3) Dr. Robert J. Glaser President - The Henry J. Kaiser Family Foundation California
- 4) Roger W. Heyns President - The William & Flora Hewlett Foundation California
- 5) Dr. David A. Hamburg
 President Carnegie Corporation
 of New York
- 6) Dr. David E. Rogers President - The Robert Wood Johnson Foundation New Jersey
- 7) Mrs. Vigdis Finnbogadottir President - Iceland
- 8) Dr. Beat Schurch Director - Nestle Foundation Switzerland



The World Health Organization 1211 Geneva 27 Switzerland The Right Honourable
Margaret Thatcher, M.P.
Prime Minister of the United Kingdom
of Great Britain and Northern
Ireland
10, Downing Street
London
United Kingdom

October 31, 1984

Dear Mrs Thatcher,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

cc: The Secretary of State for Foreign and Commonwealth Affairs, Foreign and Commonwealth Office, London

The Secretary, Department of Health and Social Security, Division IRIA, London

The Right Honourable Robert Leigh-Pemberton, Governor, Bank of England, London

United Kingdom Mission to the United Nations Office and other International Organizations at Geneva

.. ENCLS: As stated

The Right Honourable Margaret Thatcher, M.P., Prime Minister of the United Kingdom of Great Britain and Northern Ireland, London

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.

The Right Honourable Margaret Thatcher, M.P., Prime Minister of the United Kingdom of Great Britain and Northern Ireland, London

> A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

The Right Honourable Margaret Thatcher, M.P., Prime Minister of the United Kingdom of Great Britain and Northern Ireland, London

British institutions and scientists are participating actively in the work of TDR, including its scientific management. They have carried out 194 research and development projects at a total cost of US\$ 11 343 000 to the Programme. The United Kingdom is also taking part in the management of the Special Programme as a member of its Joint Coordinating Board. We are very grateful to the British institutions and scientists for their important participation, and to the Government of the United Kingdom for its financial contributions to TDR which amount to US\$ 5 151 485 up to 31 August 1984. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to consider increasing the level of the United Kingdom's financial support to TDR and to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the increased financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President,

The World Bank

H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland

October 31, 1984

Dr Robert J. Glaser
President
The Henry J. Kaiser Family
Foundation
525 Middlefield Road
Suite 200
Menlo Park
California 94025

Dear Dr Glaser,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

... ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank m. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Gustáv Husák
President of the Czechoslovak
Socialist Republic
Prague
Czechoslovakia

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Foreign Affairs of the Czechoslovak Socialist Republic,
Prague

Ministerstvo zdravotnictví Ceské socialistické Republiky, Praha Ministerstvo zdravotnictví Slovenské socialistické Republiky, Bratislava

Permanent Mission of the Czechoslovak Socialist Republic to the United Nations Office and other International Organizations at Geneva

.. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as Bacillus sphaericus, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Czechoslovak institutions and scientists are participating in the work of TDR. They have carried out three research and development projects at a

Mr Gustáv Husák, President of the Czechoslovak Socialist Republic, Prague

total cost of over US\$ 87 000 to the Programme. We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations


Development Programme

A. W. Clausen President,

The World Bank

H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Guillaume de Spoelberch General Manager Aga Khan Foundation P.O. Box 1211 Geneva 6 Switzerland

October 31, 1984

Dear Mr de Spoelberch,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand.

cc: Dr R. G. Wilson, Health Programme Officer, Aga Khan Foundation, Geneva

... ENCLS: As stated

However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

The Aga Khan Foundation is participating in the Special Programme as an official observer to its Joint Coordinating Board and we are grateful to your Foundation for this. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially and in this way to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development Programme A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Erich Honecker Chairman of the Council of State of the German Democratic Republic DDR - Berlin

October 31, 1984

Dear Mr Chairman,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Public Health of the German Democratic Republic, Berlin The Head, Department for International Economic Organizations, Ministry for Foreign Affairs of the German Democratic Republic, Berlin The Permanent Representative of the German Democratic Republic to the United Nations Office and other International Organizations at Geneva

.. ENCLS: As stated

2

Mr Erich Honecker, Chairman of the Council of State of the German Democratic Republic, Berlin

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Mr Erich Honecker, Chairman of the Council of State of the German Democratic Republic, Berlin

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Scientists of the German Democratic Republic have participated in the work of TDR and your Government is an official observer to the Programme's

Mr Erich Honecker, Chairman of the Council of State of the German Democratic Republic, Berlin

Joint Coordinating Board. We are very grateful to your Government and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank

The World Bank World Organi

H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Pál Losonczy
Chairman of the Presidential Council
of the Hungarian People's Republic
Parliament
Budapest
Hungary

October 31, 1984

Dear Mr Chairman,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Health of the Hungarian People's Republic, Department for International Relations, Ministry of Health (Egészségügyi Minisztérium), Budapest
The Minister for Foreign Affairs of the Hungarian People's Republic, Department for International Organizations, Budapest
Mr Miklós Pulai, Deputy President, National Planning Office, Budapest
The Permanent Representative of the Hungarian People's Republic to the United Nations Office and other International Organizations at Geneva

Mr Pál Losonczy, Chairman of the Presidential Council of the Hungarian People's Republic, Parliament, Budapest

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Mr Pál Losonczy, Chairman of the Presidential Council of the Hungarian People's Republic, Parliament, Budapest

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Hungarian institutions and scientists are participating in the work of TDR and have carried out one research and development project. The

Mr Pál Losonczy, Chairman of the Presidential Council of the Hungarian People's Republic, Parliament, Budapest

Government of Hungary is an official observer to the Joint Coordinating Board of the Special Programme. We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator,

United Nations Development Programme A. W. Clausen President,

The World Bank

H. Mahler, M.D. Director-General,

World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland The Honourable
Datuk Seri Dr Mahathir Mohamad
Prime Minister of Malaysia
Kuala Lumpur
Malaysia

October 31, 1984

Dear Mr Prime Minister,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Honourable Tengku Razaleigh Hamzah, Minister of Finance, Ministry of Finance, Kuala Lumpur
The Secretary General, Ministry of Health, Kuala Lumpur
The Secretary General, Ministry of Foreign Affairs, Kuala Lumpur
Permanent Mission of Malaysia to the United Nations Office and other
International Organizations at Geneva

. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as Bacillus sphaericus, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Malaysian institutions and scientists are participating in the work of TDR. They have carried out 22 research and development projects and the

The Honourable Datuk Seri Dr Mahathir Mohamad, Prime Minister of Malaysia, Kuala Lumpur

Special Programme has supported 25 training and institution strengthening projects in Malaysia at a total cost of US\$ 1 675 000 to the Programme. Malaysia is also taking an active part in the management of the Special Programme as a member of its Joint Coordinating Board. We are very grateful to your Government, its institutions and scientists for their important participation. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President,

The World Bank

H. Mahler, M.D.

Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Prem Tinasulanonda Prime Minister of the Kingdom of Thailand Bangkok Thailand

October 31, 1984

Dear Mr Prime Minister,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Public Health, Ministry of Public Health, Bangkok
The Minister of Foreign Affairs of Thailand, Bangkok
His Excellency Sommai Hoontrakool, Minister of Finance, Ministry of
Finance, Bangkok
Permanent Mission of Thailand to the United Nations Office at Geneva
and the Specialized Agencies in Switzerland

.. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Mr Prem Tinasulanonda, Prime Minister of the Kingdom of Thailand, Bangkok

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Thai institutions and scientists are participating actively in the work of TDR. They have carried out 50 research and development projects

Mr Prem Tinasulanonda, Prime Minister of the Kingdom of Thailand, Bangkok

and the Special Programme has supported 47 training and institution strengthening projects in Thailand at a total cost of US\$ 4 459 000 to the Programme. Thailand is also taking part in the management of the Special Programme as a member of its Joint Coordinating Board and the Seventh Session of the Board took place in Bangkok in June 1984. We are very grateful to your Government, its institutions and scientists for their important participation. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President,

The World Bank

H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland

The Right Honourable
David Russell Lange
Prime Minister of New Zealand
c/o Parliament House
Wellington
New Zealand

October 31, 1984

Dear Mr Prime Minister,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Foreign Affairs, Ministry of Foreign Affairs,
Wellington
The Director-General of Health, Department of Health, Wellington
Mr B. V. Galvin, Secretary to the Treasury, The Treasury, Wellington
Permanent Mission of New Zealand to the United Nations Office at Geneva
and other International Organizations in Switzerland

.. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as Bacillus sphaericus, which will destroy the larvae of disease-transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Institutions and scientists of New Zealand are participating in the work of TDR. They have carried out three research and development projects and one training course, at a total cost of US\$ 63 000 to the Programme.

We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development Programme

A. W. Clausen President, The World Bank

H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Doo-Hwan Chun President of the Republic of Korea Seoul Republic of Korea

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Foreign Affairs of the Republic of Korea, Seoul The Minister of Health and Social Affairs of the Republic of Korea, Shi Heung Kun

His Excellency Mahn-Je Kim, Minister of Finance, Ministry of Finance, Seoul

The Permanent Delegate of the Republic of Korea to International Organizations at Geneva

ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Institutions and scientists of the Republic of Korea are participating in the work of TDR. They have carried out seven research and development

projects at a total cost of US\$ 115 000 to the Programme. The Republic of Korea is also taking an active part in the management of the Special Programme as a member of its Joint Coordinating Board. We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr C. V. Devan Nair
President of the Republic
of Singapore
Singapore
Republic of Singapore

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister for Health, Singapore The Honourable Tony Tan Keng Yam, Minister for Finance, Ministry of Finance, Singapore Permanent Mission of the Republic of Singapore to the United Nations Office at Geneva and other Specialized Agencies in Switzerland

... ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Singaporean institutions and scientists are participating in the work of TDR. They have carried out eight research and development projects and

the Special Programme has supported one training project in Singapore at a total cost of US\$ 378 000 to the Programme. We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,


Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank

H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Vojo Srzentić
President of the Assembly of the Socialist Federal Republic of Yugoslavia
Palata Federacije
Bulevar Lenjina 2
11070 Novi Beograd
Yugoslavia

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Federal Secretary for Foreign Affairs, Belgrade
His Excellency Vlado Klemencić, Federal Secretary for Finance, Federal
Secretariat for Finance, Belgrade
The Permanent Representative of the Socialist Federal Republic of

Yugoslavia to the United Nations Office at Geneva and Specialized Agencies in Europe

The President, Federal Committee for Labour, Health and Social Welfare, Novi Beograd

... ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Mr Vojo Srzentić, President of the Assembly of the Socialist Federal Republic of Yugoslavia, Novi Beograd

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Yugoslav institutions and scientists are participating in the work of TDR and they have carried out one research and development project. We are

very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Patrick Hillery President of Ireland <u>Dublin</u> Ireland

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister for Foreign Affairs, Department of Foreign Affairs of Ireland, Dublin The Honourable Alan M. Dukes, T.D., Minister for Finance, Department of Finance, Dublin The Secretary, Department of Health, Dublin Permanent Mission of Ireland to the United Nations Office and to the Specialized Agencies at Geneva

ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Irish institutions and scientists are participating in the work of TDR and have carried out one research and development project. We are grateful

to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development Programme A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Muhammadu Buhari
Head of State of the Federal
Republic of Nigeria
State House
Lagos
Nigeria

October 31, 1984

Dear Mr Buhari,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Health, Federal Ministry of Health, Lagos
The Honourable Dr Onaolapo Soleye, Federal Minister of Finance, Lagos
Permanent Mission of the Federal Republic of Nigeria to the United
Nations Office and the International Organizations at Geneva

... ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Nigerian institutions and scientists are participating actively in the work of TDR. They have carried out 17 research and development projects

and the Special Programme has supported 56 training and institution strengthening projects in Nigeria at a total cost of US\$ 3 805 000 to the Programme. Nigeria has also taken part in the management of the Special Programme as a member of its Joint Coordinating Board in 1978 and 1979 and again from 1981 - 1983. The Government of Nigeria is currently an official observer to the Board. We are very grateful to the Nigerian institutions and scientists for their important participation, and to the Government of Nigeria for its financial contributions to TDR of US\$ 421 389 up to 1981. We were pleased to receive in August 1983 your Government's pledge of further financial contributions to the Programme in the amount of 50 000 Naira annually for five years starting from 1982. In view of the tasks to be accomplished and the opportunities before us, we are asking you to continue and to consider increasing the level of Nigeria's financial support to TDR and to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the increased financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank

Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Yasuhiro Nakasone Prime Minister of Japan Tokyo Japan

October 31, 1984

Dear Mr Prime Minister,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Health and Welfare, Ministry of Health and Welfare, Japanese Government, Tokyo

The Minister for Foreign Affairs of Japan, Ministry for Foreign Affairs, Tokyo

His Excellency Noboru Takeshita, Minister of Finance, Ministry of Finance, Tokyo

The Permanent Representative of Japan to the United Nations Office and to the International Organizations at Geneva

ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Japanese institutions and scientists are playing an important role in the work of TDR. They have carried out 20 research and development

projects at a total cost of US\$ 779 000 to TDR, and are taking part in the scientific management of the Programme. The Government of Japan is an official observer to the Joint Coordinating Board of the Special Programme. We are very grateful to the Japanese institutions and scientists for their important participation, and to the Government of Japan for its financial contributions to TDR which amount to US\$ 300 000 up to 31 August 1984. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to consider increasing the level of Japan's financial support to TDR and to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the increased financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development

Programme

A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Ronald Reagan President of the United States of America The White House Washington, D.C.

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

cc: The Secretary of State, Attention: IO-HNP, Department of State, Washington, D.C.

The Honorable Donald T. Regan, Secretary of the Treasury, Department of the Treasury, Washington, D.C.

The Assistant Secretary for Health, Department of Health and Human Services, Washington, D.C.

The United States Representative to the United Nations Office and other International Organizations at Geneva

... ENCLS: As stated

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.

Mr Ronald Reagan, President of the United States of America, Washington, D.C.

 A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Mr Ronald Reagan, President of the United States of America, Washington, D.C.

Institutions and scientists of the United States of America are participating actively in the work of TDR, including its scientific management. They have carried out 366 research and development projects and the Special Programme has supported 4 training projects in the United States at a total cost of US\$ 22 540 000 to the Programme. The United States of America is also taking part in the management of the Special Programme as a member of its Joint Coordinating Board. We are very grateful to the American institutions and scientists for their important participation, and to the Government of the United States of America for its financial contributions to TDR which amount to US\$ 20 403 912 up to 31 August 1984. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to consider increasing the level of your Government's financial support to TDR and to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the increased financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Dr Rudolf Kirchschläger President of the Republic of Austria Hofburg 1010 Vienna Austria

October 31, 1984

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the

cc: The Federal Minister of Health and Environmental Protection,
Bundesministerium für Gesundheit und Umweltschutz, Vienna
Seine Exzellenz Dr Herbert Salcher, Bundesminister für Finanzen, Vienna
The Permanent Representative of Austria to the United Nations Office
and the Specialized Agencies at Geneva

ENCLS: As stated

individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

 Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.

- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Austria has taken an active part in the management of the Special Programme as a member of its Joint Coordinating Board in 1979 and 1980 and subsequently as an official observer to the Board. We are very grateful to the Government of Austria for its participation and for its financial contributions to TDR which amount to US\$ 536 511 up to 31 August 1984. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to consider increasing the level of Austria's financial support to TDR and to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the increased financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President,

The World Bank

H. Mahler, M.D. Director-General, World Health Organization



The World Health Organization 1211 Geneva 27 Switzerland Mr Franklin A. Thomas President The Ford Foundation 320 East 43rd Street New York, N.Y. 10017

October 31, 1984

Dear Mr Thomas,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand.

cc: Mr Oscar Harkavy, Chief Program Officer, Program Division - Urban Poverty Program, The Ford Foundation, New York

... ENCLS: As stated

However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

The Ford Foundation is participating in the Special Programme as an official observer to its Joint Coordinating Board and we are grateful to your Foundation for this. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially and in this way to work with us to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland Dr R. C. Tress
Director
The Leverhulme Trust
15-19 New Fetter Lane
London, EC4A 1NR
United Kingdom

October 31, 1984

Dear Dr Tress,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

Dr R. C. Tress, Director, The Leverhulme Trust, London

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Trust in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland Ms Margaret E. Mahoney President The Commonwealth Fund One East 75th Street New York, N.Y. 10021

October 31, 1984

Dear Ms Mahoney,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

.. ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as Bacillus sphaericus, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Fund in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator. United Nations

Development

Programme

A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland

October 31, 1984

Mr Roger W. Heyns
President
The William and Flora Hewlett
Foundation
525 Middlefield Road
Suite 200
Menlo Park
California 94025

Dear Mr Heyns,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse

Administrator, United Nations Development Programme A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland Dr David A. Hamburg President Carnegie Corporation of New York 437 Madison Avenue New York, N.Y. 10022

October 31, 1984

Dear Dr Hamburg,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Corporation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland

Dr David E. Rogers President The Robert Wood Johnson Foundation P.O. Box 2316 Princeton, N.J. 08540

October 31, 1984

Dear Dr Rogers,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

ENCLS: As stated

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as Bacillus sphaericus, which will destroy the larvae of diseasetransmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development Programme

A. W. Clausen President. The World Bank

H. Mahler, M.D. Director-General. World Health

Organization



The World Health Organization 1211 Geneva 27 Switzerland Mrs Vigdís Finnbogadóttir President of the Republic of Iceland Stjornarradshusinu V-Laukjartorg 101 Reykjavik Iceland

October 31, 1984

Dear Mrs Finnbogadóttir,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister for Foreign Affairs of Iceland, Reykjavik
The Minister of Health and Social Security, Reykjavik
His Excellency Matthias A. Mathiesen, Minister of Commerce, Ministry of
Commerce, Reykjavik
Permanent Mission of Iceland to the United Nations Office at Geneva

.. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations


Development Programme

A. W. Clausen President, The World Bank

Director-General, World Health

H. Mahler, M.D.

Organization



The World Health Organization 1211 Geneva 27 Switzerland Dr Beat Schürch Director Nestlé Foundation B.P. 1051 1001 Lausanne Switzerland

October 31, 1984

Dear Dr Schürch,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthdays, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

... ENCLS: As stated

Dr Beat Schürch, Director, Nestlé Foundation, Lausanne

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past six years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams — in fundamental research laboratories, in hospital clinics and in village health centres — to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.

- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1975 until 31 August 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Foundation in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations Development

Programme

A. W. Clausen President, The World Bank



The World Health Organization 1211 Geneva 27 Switzerland Mr Sayed Ali Khamenei
President of the Islamic Republic
of Iran
Teheran
Islamic Republic of Iran

January 23, 1985

Dear Mr President,

We take the liberty of soliciting your support for a unique venture in international collaboration. This venture in research and development is an investment in the future of mankind and will require years of work and sustained financial support. However, we are convinced that the results will have a profound impact on the health and well-being of humanity.

The Special Programme for Research and Training in Tropical Diseases (TDR) - co-sponsored by the United Nations Development Programme, the World Bank and the World Health Organization - seeks to develop the means to control six major tropical diseases which today afflict or threaten over one thousand million people living in developing countries. We attach for your information a booklet describing in more detail the work and achievements of the Special Programme.

In spite of the explosive growth of knowledge in the biological sciences over the past 30 years, little progress has been made towards the control of these diseases. In fact the menace is increasing.

Millions of children die from malaria before reaching their fifth birthday, and millions of those who reach adulthood are incapacitated by one or more tropical infections. They are sentenced to spend their lives on the treadmill of illness and poverty with no hope of improving the lot of their families or their communities.

cc: The Minister of Health, Ministry of Health, International Health Relations Department, Teheran

Monsieur le Ministre des Affaires étrangères de la République islamique d'Iran, Téhéran

His Excellency Dr Hossein Namazi, Minister of Economic Affairs and Finance, Ministry of Economic Affairs and Finance, Teheran

Mission permanente de la République islamique d'Iran auprès de l'Office des Nations Unies et des autres Organisations internationales à Genève

.. ENCLS: As stated

The devastating blow, to the individual and the family, of an acute attack of malaria at harvest time or of permanent loss of sight by the age of 25 from river blindness (onchocerciasis) is easy to understand. However, the social and economic impacts upon a community and a country when tropical diseases strike down hundreds of thousands of people, go far beyond the individual or gross statistics. In fact, epidemics of malaria, sleeping sickness and river blindness often drive self-sufficient communities into states of dependent poverty.

The destructive symbiosis of disease and poverty must, and can be replaced by the synergism of health and productivity. To bring this about, the tropical countries require both the tools for prevention and treatment of the tropical diseases and the scientific and technical capabilities to assure their effective application. These are the goals of TDR.

Over the past seven years, TDR has challenged and stimulated researchers at institutions throughout the world to work together toward these ends. Thousands of scientists in universities, research institutions, government ministries and industry have responded and are now working as members of TDR teams - in fundamental research laboratories, in hospital clinics and in village health centres - to build the new tools and prepare them for use in the villages of the tropics. TDR has catalysed the linking of research activities into an effective worldwide network and has focused the new methods and knowledge of the biological sciences upon the tropical diseases.

The results have been remarkable and research carried out both within and outside the Special Programme has brought about significant progress. Some new tools for disease control have already reached the stage of actual application in the field, while others are close to it. Examples of major developments towards the control of the diseases include:

- A biological agent, <u>Bacillus thuringiensis</u> H-14, to control the flies that spread river blindness is being used extensively in West Africa and is being tested against malaria-carrying mosquitos.
- A new drug, mefloquine, for the treatment of malaria infections resistant to standard therapy has been registered for use.
- Vaccines which may treat and prevent leprosy are in the early stages of testing in man. However, the tests will take five to eight years to complete because of the slow natural history of the disease.
- Simple kits to measure the sensitivity of malaria parasites to drugs to assure the correct choice of treatment are being used widely.
- A simple test to diagnose sleeping sickness (African trypanosomiasis) at the village level, and thus permit early intervention, is ready for widespread application.

Among significant achievements at earlier stages of development are the following:

- Vaccines against malaria are now a real possibility following the identification and production of the substances in the parasite responsible for man's immune reactions against them.
- A totally new family of compounds for the treatment of malaria, based on a traditional Chinese remedy called Qinghaosu, has been synthesized and testing has begun.
- Drugs for the treatment of river blindness, critical for the control of this disease, are being synthesized and tested.
- Natural biological agents are being tested in the field, such as <u>Bacillus sphaericus</u>, which will destroy the larvae of disease- transmitting insects and recycle themselves and in this way prolong their effectiveness.
- Simple and effective diagnostic tests vital to all disease control programmes - are being developed for Chagas' disease, schistosomiasis, malaria and leprosy.

Scientists and institutions in over 120 countries participate in TDR and provide the vision, knowledge and facilities required for the work. So far, their progress has been outstanding, while the Programme's catalytic effects have kept costs low. In short, we believe TDR to be one of the most cost-effective investments in health and development and one which merits your support. However, bringing a new drug or vaccine from the laboratory to the needy family in the village takes many years of work, and for this TDR requires both adequate and sustained financial support.

TDR depends entirely upon voluntary contributions. From 1974 until 31 October 1984, 27 governments and 11 other organizations, together with the three co-sponsoring agencies, have contributed over US\$ 155 million to the Programme (see attached table). However, available funds have fallen short of the minimum required (about US\$ 33 million per year) to keep the Programme moving ahead. Unless contributions are increased and sustained, TDR will have to abandon many promising initiatives towards new and effective tools to control the diseases. Malaria, sleeping sickness, river blindness and leprosy will continue to spread and thwart any hope of self reliance for the people living in the tropics.

We are convinced that the partnership of modern science and the Special Programme can go far to break the cycle of disease and poverty. Scientists from both the public and private sectors are already doing their part and it is now up to governments and agencies to provide TDR with the funds necessary to complete the work.

Iranian institutions and scientists are participating in the work of TDR, including its scientific management. They have carried out one

research and development project and the Special Programme has supported the training of an Iranian scientist. The Government of the Islamic Republic of Iran is an official observer to the Joint Coordinating Board of the Special Programme. We are very grateful to your Government, its institutions and scientists for their participation and we hope it will increase. However, in view of the tasks to be accomplished and the opportunities before us, we are asking you to support TDR financially as well as technically and in this way to work with us at all levels of the Programme to transform the opportunities of today into the new drugs and vaccines of tomorrow.

We sincerely hope that you will give serious consideration to our request for the financial participation of your Government in the Special Programme and look forward to hearing from you at your earliest convenience. We should be grateful if you would send your reply to Dr Halfdan Mahler, Director-General of the World Health Organization.

Sincerely,

Bradford Morse Administrator, United Nations

Development Programme A. W. Clausen President, The World Bank